Mineralys Therapeutics, Inc. (MLYS) Financials

MLYS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 667.9 million 116.9 million
March 31, 2026 652.9 million 14.7 million
Dec. 31, 2025 661.8 million 15.1 million
Sept. 30, 2025 599.9 million 23.5 million

MLYS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -32.6 million 7.4 million
March 31, 2026 -39.5 million 6.5 million
Dec. 31, 2025 -37.9 million 5.3 million
Sept. 30, 2025 -28.9 million 5.8 million

MLYS Net Income

No data available :(

MLYS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 661.4 million 97.6 million -
March 31, 2026 646.1 million - -
Dec. 31, 2025 656.6 million - -
Sept. 30, 2025 217.6 million - -

MLYS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 84.7 million
March 31, 2026 82.8 million
Dec. 31, 2025 80.5 million
Sept. 30, 2025 70.6 million

MLYS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 221.4 million 24.7 million -
March 31, 2026 - 24.4 million 21.0 million -
Dec. 31, 2025 15000 24.4 million 13.9 million -
Sept. 30, 2025 - 31.5 million 9.7 million -

MLYS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 6000
Dec. 31, 2025 - 13000
Sept. 30, 2025 - 15000

MLYS

Price: $25.66

52 week price:
12.59
47.65

Earnings Per Share: -4.20 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 2.4 billion

Links: